FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034644499> ?p ?o ?g. }

• W2034644499 endingPage "2520" @default.
• W2034644499 startingPage "2510" @default.
• W2034644499 abstract "Psoriasis, a tumor necrosis factor alpha (TNFα)-governed inflammatory disorder with prominent dysregulation of cutaneous vascular functions, has evolved into a model disorder for studying anti-inflammatory therapies. We present experimental in vitro and in vivo data on 1-O-octadecyl-2-O-(2-(myo-inositolyl)-ethyl)-sn-glycero-3-(R/S)-phosphatidyl-choline (Ino-C2-PAF), the lead compound of a class of synthetic glycosylated phospholipids, in anti-inflammatory therapy. Ino-C2-PAF strongly induced apoptosis only in TNFα-stimulated, but not in untreated human vascular endothelial cells. Moreover, TNFα-induced endothelial adhesion molecules that mediated the rolling and firm adhesion of leukocytes (vascular cell adhesion protein-1 (VCAM-1), E-selectin, and ICAM-1) were selectively downregulated by Ino-C2-PAF. Similarly, expression of L-selectin, VCAM-1 receptor α4β1 integrin, and lymphocyte function-associated antigen-1 on human peripheral blood mononuclear cells was reduced without induction of apoptosis. Functionally, these changes were accompanied by significant impairment of rolling and adhesion of human peripheral blood lymphocytes on TNFα-activated endothelial cells in a dynamic flow chamber system. When the therapeutic potential of Ino-C2-PAF was assessed in two complementary mouse models of psoriasis, K5.hTGFβ1 transgenic and JunB/c-Jun-deficient mice, Ino-C2-PAF led to significant alleviation of the clinical symptoms and normalized the pathological cutaneous changes including vascularization. There were no overt adverse effects. These findings suggested that Ino-C2-PAF is a potential candidate in the therapy of inflammatory skin diseases that include abnormal vascular functions. Psoriasis, a tumor necrosis factor alpha (TNFα)-governed inflammatory disorder with prominent dysregulation of cutaneous vascular functions, has evolved into a model disorder for studying anti-inflammatory therapies. We present experimental in vitro and in vivo data on 1-O-octadecyl-2-O-(2-(myo-inositolyl)-ethyl)-sn-glycero-3-(R/S)-phosphatidyl-choline (Ino-C2-PAF), the lead compound of a class of synthetic glycosylated phospholipids, in anti-inflammatory therapy. Ino-C2-PAF strongly induced apoptosis only in TNFα-stimulated, but not in untreated human vascular endothelial cells. Moreover, TNFα-induced endothelial adhesion molecules that mediated the rolling and firm adhesion of leukocytes (vascular cell adhesion protein-1 (VCAM-1), E-selectin, and ICAM-1) were selectively downregulated by Ino-C2-PAF. Similarly, expression of L-selectin, VCAM-1 receptor α4β1 integrin, and lymphocyte function-associated antigen-1 on human peripheral blood mononuclear cells was reduced without induction of apoptosis. Functionally, these changes were accompanied by significant impairment of rolling and adhesion of human peripheral blood lymphocytes on TNFα-activated endothelial cells in a dynamic flow chamber system. When the therapeutic potential of Ino-C2-PAF was assessed in two complementary mouse models of psoriasis, K5.hTGFβ1 transgenic and JunB/c-Jun-deficient mice, Ino-C2-PAF led to significant alleviation of the clinical symptoms and normalized the pathological cutaneous changes including vascularization. There were no overt adverse effects. These findings suggested that Ino-C2-PAF is a potential candidate in the therapy of inflammatory skin diseases that include abnormal vascular functions. carboxyfluorescein diacetate N-succinimidyl ester human umbilical vein endothelial cells 1-O-octadecyl-2-O-(2-(myo-inositolyl)-ethyl)-sn-glycero-3-(R/S)-phosphatidyl-choline peripheral blood mononuclear cell" @default.
• W2034644499 created "2016-06-24" @default.
• W2034644499 creator A5009731881 @default.
• W2034644499 creator A5055654335 @default.
• W2034644499 creator A5063797588 @default.
• W2034644499 creator A5067797014 @default.
• W2034644499 creator A5075850310 @default.
• W2034644499 creator A5089977110 @default.
• W2034644499 creator A5091904035 @default.
• W2034644499 date "2014-10-01" @default.
• W2034644499 modified "2023-10-03" @default.
• W2034644499 title "Inositoylated Platelet-Activating Factor (Ino-C2-PAF) Modulates Dynamic Lymphocyte–Endothelial Cell Interactions and Alleviates Psoriasis-Like Skin Inflammation in Two Complementary Mouse Models" @default.
• W2034644499 cites W1543621601 @default.
• W2034644499 cites W1557259482 @default.
• W2034644499 cites W1571129984 @default.
• W2034644499 cites W1590241149 @default.
• W2034644499 cites W1782747004 @default.
• W2034644499 cites W1951152790 @default.
• W2034644499 cites W1964584856 @default.
• W2034644499 cites W1968121242 @default.
• W2034644499 cites W1974381618 @default.
• W2034644499 cites W1977874369 @default.
• W2034644499 cites W1984238182 @default.
• W2034644499 cites W1991062077 @default.
• W2034644499 cites W1993941415 @default.
• W2034644499 cites W2011246962 @default.
• W2034644499 cites W2012097026 @default.
• W2034644499 cites W2015460060 @default.
• W2034644499 cites W2018517153 @default.
• W2034644499 cites W2020179490 @default.
• W2034644499 cites W2034654881 @default.
• W2034644499 cites W2038697002 @default.
• W2034644499 cites W2045802427 @default.
• W2034644499 cites W2046234296 @default.
• W2034644499 cites W2049177466 @default.
• W2034644499 cites W2057434487 @default.
• W2034644499 cites W2057448387 @default.
• W2034644499 cites W2059846269 @default.
• W2034644499 cites W2061687700 @default.
• W2034644499 cites W2063592572 @default.
• W2034644499 cites W2063628490 @default.
• W2034644499 cites W2074534566 @default.
• W2034644499 cites W2075932475 @default.
• W2034644499 cites W2078299820 @default.
• W2034644499 cites W2085530372 @default.
• W2034644499 cites W2094835614 @default.
• W2034644499 cites W2102688877 @default.
• W2034644499 cites W2111858177 @default.
• W2034644499 cites W2121126920 @default.
• W2034644499 cites W2124416450 @default.
• W2034644499 cites W2128387219 @default.
• W2034644499 cites W2135787471 @default.
• W2034644499 cites W2140118273 @default.
• W2034644499 cites W2154324108 @default.
• W2034644499 cites W2170262191 @default.
• W2034644499 cites W2561759163 @default.
• W2034644499 cites W4233561050 @default.
• W2034644499 cites W4236396577 @default.
• W2034644499 cites W4252483888 @default.
• W2034644499 doi "https://doi.org/10.1038/jid.2014.170" @default.
• W2034644499 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24714204" @default.
• W2034644499 hasPublicationYear "2014" @default.
• W2034644499 type Work @default.
• W2034644499 sameAs 2034644499 @default.
• W2034644499 citedByCount "7" @default.
• W2034644499 countsByYear W20346444992016 @default.
• W2034644499 countsByYear W20346444992017 @default.
• W2034644499 countsByYear W20346444992018 @default.
• W2034644499 countsByYear W20346444992021 @default.
• W2034644499 countsByYear W20346444992023 @default.
• W2034644499 crossrefType "journal-article" @default.
• W2034644499 hasAuthorship W2034644499A5009731881 @default.
• W2034644499 hasAuthorship W2034644499A5055654335 @default.
• W2034644499 hasAuthorship W2034644499A5063797588 @default.
• W2034644499 hasAuthorship W2034644499A5067797014 @default.
• W2034644499 hasAuthorship W2034644499A5075850310 @default.
• W2034644499 hasAuthorship W2034644499A5089977110 @default.
• W2034644499 hasAuthorship W2034644499A5091904035 @default.
• W2034644499 hasBestOaLocation W20346444991 @default.
• W2034644499 hasConcept C137061746 @default.
• W2034644499 hasConcept C16224149 @default.
• W2034644499 hasConcept C17991360 @default.
• W2034644499 hasConcept C185592680 @default.
• W2034644499 hasConcept C202751555 @default.
• W2034644499 hasConcept C203014093 @default.
• W2034644499 hasConcept C2776914184 @default.
• W2034644499 hasConcept C2779020240 @default.
• W2034644499 hasConcept C2780564577 @default.
• W2034644499 hasConcept C502942594 @default.
• W2034644499 hasConcept C55493867 @default.
• W2034644499 hasConcept C71924100 @default.
• W2034644499 hasConcept C98274493 @default.
• W2034644499 hasConceptScore W2034644499C137061746 @default.
• W2034644499 hasConceptScore W2034644499C16224149 @default.
• W2034644499 hasConceptScore W2034644499C17991360 @default.
• W2034644499 hasConceptScore W2034644499C185592680 @default.
• W2034644499 hasConceptScore W2034644499C202751555 @default.
• W2034644499 hasConceptScore W2034644499C203014093 @default.

• next